IDH-1 is now being targeted for therapeutic use for instance by Agios Pharmaceuticals, who are currently moving forward with the drug candidate AG-120 after their tool compound inhibitors were found to be successful in glioma xenografts (Rohle et al, 2013). The gene discussed is IDH1; the disease is central nervous system cancer.